programmed death-ligand 1 + interleukin-7

A **programmed death-ligand 1 + interleukin-7** therapeutic is a bifunctional **anti-PD-L1/IL-7 immunocytokine** concept in which a PD-L1-binding antibody is fused to the cytokine IL-7 to combine checkpoint blockade with localized T-cell supportive cytokine signaling. The intended mechanism is to block the **PD-1/PD-L1 immune checkpoint axis** while delivering **IL-7 receptor stimulation** in the tumor microenvironment to enhance survival, expansion, and function of antitumor lymphocytes and potentially reduce the systemic toxicity associated with untargeted cytokine therapy. Publicly visible evidence supports the existence of this modality as a preclinical or patent-stage fusion-protein approach, including disclosures from **Suzhou Zelgen Biopharmaceutical** describing an anti-PD-L1 antibody fused to IL-7 for oncology use, but I could not identify a clearly established unique international nonproprietary name, brand name, or a widely recognized clinical-stage product name that maps unambiguously to the query.

Other names

anti-PD-L1 antibody + interleukin-7anti-PD-L1 antibody and IL-7 fusion proteinanti-PD-L-1 antibody and IL-7 fusion proteinanti-PD-L 1 antibody and IL-7 fusion proteinbifunctional fusion protein composed of anti-PD-L1 antibody and IL-7PD-L1 + IL-7 fusion protein